AA, R., & M, R. (2022, April). The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes, Metabolic Syndrome and Obesity.
Chicagoスタイル(17版)引用形式AA, Rizvi, , Rizzo M. "The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction." Diabetes, Metabolic Syndrome and Obesity Apr. 2022.
MLA(9版)引用形式AA, Rizvi, , Rizzo M. "The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction." Diabetes, Metabolic Syndrome and Obesity, Apr. 2022.
警告: この引用は必ずしも正確ではありません.